News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Shire ADHD Treatment Recommended by Europe's New Centralized Authorization Procedure

July 24, 2015
Article

July 24, 2015.

The European Medicines Agency (EMA) has recommended granting a marketing authorization for Shire's Intuniv (guanfacine) to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years old for whom stimulants are not suitable or tolerated or have shown to be ineffective. This is the first treatment for ADHD in the European Union (EU) to be recommended through the centralized authorization procedure.   Since the 1950s stimulants have been the standard medication therapy for ADHD. Intuniv has a different mechanism of action. It is expected to improve the symptoms by initiating a response from neurons in regions of the brain associated with attention, organisation, planning and impulse control.     During the drug evaluation, the Committee for Medicinal Products for Human Use (CHMP) sought input from external experts, both clinicians and patient’s representatives, and invited the mother of an ADHD patient and a young adult affected by ADHD to share their experience during the Committee meeting. This is part of a pilot project started in September 2014 to bring patients’ and carers’ views and values to the assessment of medicines throughout their lifecycle.  

Recent Videos
Asembia 2025: Digital Health and Biosimilars Shape the Future of Pharmacy
Asembia 2025: Digital Health and Biosimilars Shape the Future of Pharmacy
Asembia 2025: Why AI Could Be the Key to Solving Access Challenges in Healthcare
Asembia 2025: Why AI Could Be the Key to Solving Access Challenges in Healthcare
Ted Sweetser
Using AI and RWD to Drive Creative Decision-Making
Using RWD to Create Personalized Engagement
Using RWD to Create Personalized Engagement
Ted Sweetser
Overcoming Pharma Marketing Challenges with AI
Ted Sweetser
How AI is Shaking Up Pharma Marketing
Bridging the Cardiologist Shortage with AI-Powered Heart Scans
Bridging the Cardiologist Shortage with AI-Powered Heart Scans
Crucial Technological Advancements for Future Pandemic Preparedness and Supply Chain Stability
Crucial Technological Advancements for Future Pandemic Preparedness and Supply Chain Stability
The Evolution of the Intersection of Technology and Law in the Bay Area
The Evolution of the Intersection of Technology and Law in the Bay Area
Matthew Yelovich, Cleary Gottlieb, Theranos Case
Theranos Case Implications for Corporate Governance & Accountability
Related Content
Advertisement

Stock.adobe.com

DeepL Announces HIPAA-Compliant AI

Mike Hollan
May 15th 2025
Article

The protection and privacy of healthcare data is a massive hurdle for the new technology to overcome.


Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
February 10th 2025
Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.


Revenue Optimization: The Money Matters—That Matter Most

Revenue Optimization: The Money Matters—That Matter Most

Jesse Mendelsohn
May 9th 2025
Article

Navigating technology and regulatory shifts in pharma revenue management.


Stock.adobe.com

Blue Cross Blue Shield of Massachusetts Adds Virtual-First Primary Care Option

Mike Hollan
May 9th 2025
Article

The provider hopes that this option will be a solution to the state’s primary care physician shortage.


Stock.adobe.com

FDA Announces ‘Aggressive’ AI Implementation Timeline

Mike Hollan
May 8th 2025
Article

Commissioner Markary announced the plans alongside the results of a generative AI pilot for scientific reviewers.


Lunit

Lunit’s AI Technology to Power German Radiology Network

Mike Hollan
May 8th 2025
Article

The pharma tech company announced a deal with Starvision to roll out its services across the network over the next five years.

Related Content
Technology
Advertisement

Stock.adobe.com

DeepL Announces HIPAA-Compliant AI

Mike Hollan
May 15th 2025
Article

The protection and privacy of healthcare data is a massive hurdle for the new technology to overcome.


Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
February 10th 2025
Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.


Revenue Optimization: The Money Matters—That Matter Most

Revenue Optimization: The Money Matters—That Matter Most

Jesse Mendelsohn
May 9th 2025
Article

Navigating technology and regulatory shifts in pharma revenue management.


Stock.adobe.com

Blue Cross Blue Shield of Massachusetts Adds Virtual-First Primary Care Option

Mike Hollan
May 9th 2025
Article

The provider hopes that this option will be a solution to the state’s primary care physician shortage.


Stock.adobe.com

FDA Announces ‘Aggressive’ AI Implementation Timeline

Mike Hollan
May 8th 2025
Article

Commissioner Markary announced the plans alongside the results of a generative AI pilot for scientific reviewers.


Lunit

Lunit’s AI Technology to Power German Radiology Network

Mike Hollan
May 8th 2025
Article

The pharma tech company announced a deal with Starvision to roll out its services across the network over the next five years.

Advertisement
Advertisement
Advertisement
x
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.